UK Biotechnology Market Overview

The UK biotechnology market was valued at USD 22.00 Billion in 2024 and is forecasted to reach USD 41.47 Billion by 2033, exhibiting a CAGR of 7.22% during the period 2025-2033. Growth is driven by increasing chronic diseases, advancements in genomics and gene editing, robust government support, and rising application in sustainable agriculture. The market is also propelled by innovations in personalized medicine and bioinformatics, making it a dynamic and evolving sector.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

UK Biotechnology Market Key Takeaways

• Current Market Size: USD 22.00 Billion in 2024
• CAGR: 7.22% (2025-2033)
• Forecast Period: 2025-2033
• The market growth is supported by rising demand for personalized medicine driven by genomics and bioinformatics.
• Strong governmental initiatives like Innovate UK's £1.1 billion budget stimulate innovation and private investment.
• The reagents segment accounts for the largest product share at 45.8%, vital for biochemical and research applications.
• DNA sequencing leads the technology segment with a 36.8% share due to its role in genomics and diagnostics.
• Healthcare dominates the application segment with 49.6%, driven by chronic diseases and advanced therapeutics.

Sample Request Link: https://www.imarcgroup.com/UK-Biotechnology-Market/requestsample

UK Biotechnology Market Growth Factors

The UK biotechnology market benefits extensively from strong government support which fuels growth and innovation. Bodies such as UK Research and Innovation (UKRI) and Innovate UK provide crucial capital for early-stage ventures. Innovate UK operates with an annual £1.1 billion budget, supporting over 450,000 innovators and generating £3.61 in private-sector investment for every £1 spent. Government-backed programs like Life Sciences Vision 2030 and R&D tax incentives further encourage private investment in biopharma and medical technology, while science parks and university-industry collaborations strengthen the ecosystem enabling translation of research into market therapies.

Rising demand for personalized medicine and genomics also drives the market. Technological progress in genome sequencing, bioinformatics, and data analytics enables tailored therapies based on individual genetic profiles. The NHS Genomic Medicine Service processed over 810,000 genomic tests in 2024, an 8% increase over the previous year. Projects like the 100,000 Genomes Project enhance the UK's role in precision healthcare, attracting investments in biotech firms developing cell and gene therapies, rare disease solutions, and molecular diagnostics.

A growing need for sustainable agricultural solutions propels the biotechnology market as the farming sector faces climate change and resource shortages. Biotechnology aids in developing genetically modified crops resilient against pests and climatic extremes, reducing pesticide use and environmental impact. British public opinion shows 69% support for gene editing in agriculture. Advances in bioinformatics and genomics also improve crop nutrient content and growth traits. Additionally, bio-based fertilizers and biopesticides that enhance soil quality and reduce contamination risks further the push toward sustainable agriculture.

UK Biotechnology Market Segmentation

By Product Type

• Instruments
• Reagents: Largest market share at 45.8%, essential for biochemical reactions, cell cultures, molecular biology, and personalized medicine research. Innovations in enzyme-linked reagents and PCR kits enhance sensitivity and efficiency.
• Software and Services

By Technology

• Nanobiotechnology
• Tissue Engineering and Regeneration
• DNA Sequencing: Holds the largest segment with 36.8% share due to critical roles in genomics, personalized medicine, and molecular diagnostics. Advanced NGS technologies support large-scale projects and the development of tailored therapies.
• Cell-Based Assays
• Fermentation
• PCR Technology
• Chromatography
• Others

By Application

• Healthcare: Dominates 49.6% of the market, fueled by chronic and genetic diseases, growing aging population, and demand for advanced therapeutics like monoclonal antibodies, vaccines, and cell therapies.
• Food and Agriculture
• Natural Resources and Environment
• Industrial Processing
• Bioinformatics
• Others

Regional Insights

London leads the UK biotechnology market owing to world-class research universities, advanced healthcare infrastructure, and numerous biotech startups. It benefits from strong government funding, private investments, and skilled talent for innovations in genomics, diagnostics, and personalized medicine. The South East region, close to London, supports pharmaceutical and biotech collaborations through vibrant startup ecosystems and research centers. The North West has a growing biotech cluster focused on bioprocessing and pharmaceuticals, supported by manufacturing and NHS partnerships. Other regions like East of England, South West, Scotland, West Midlands, Yorkshire and The Humber, East Midlands, and others contribute through specialized biotech sectors and university-industry collaborations.

Recent Developments & News

• March 2025: Celex Oncology unveiled a novel investigational treatment targeting sodium overload in tumor cells to control metastatic cancer, involving VGSC inhibitors and monoclonal antibodies.
• February 2025: Biocon Ltd launched Liraglutide under Liraglutide Biocon and Biolide brands in the UK for diabetes and obesity management after MHRA approval.
• February 2025: Sortera Bio commercialized Deep Screening, an AI-driven platform for rapid biological discovery, developed at MRC Laboratory of Molecular Biology.
• February 2025: Tropic prepared to launch non-browning and extended shelf-life bananas using CRISPR, expanded resistant banana trials and secured global regulatory approvals.
• January 2025: Verdiva Bio launched as a clinical-stage company focused on obesity and cardiometabolic therapies, securing USD 411 Million Series A financing.

Key Players

• Celex Oncology
• Biocon Ltd
• Sortera Bio
• Tropic
• Verdiva Bio

Customization Note:- https://www.imarcgroup.com/request?type=report&id=24913&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302